Totarol
CAS 511-15-9
Totarol (CAS 511-15-9) is a pharmaceutical compound with 7 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | MIC | 27.428823529411762 ug.mL-1 | 17 | - |
| - | Potency | 27168.28823529412 nM | 17 | - |
| - | IC50 | 24295 nM | 8 | - |
| - | AC50 | 3327 nM | 2 | - |
| - | MIC | 2500 nM | 2 | - |
| - | EC50 | 3500 nM | 1 | - |
| - | Kd | 11000 nM | 1 | - |
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| TOTAROL | 1600439 | SU | MTHSPL |
| totarol | 1600439 | IN | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Totarol used for in pharmaceutical contexts?
Totarol (CAS 511-15-9) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Totarol?
No adverse-event association or SIDER side-effect rows are rendered for Totarol in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Totarol also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Totarol with EU status "permitted".
What clinical phase is Totarol in?
No phase 1-4 clinical development badge is rendered for Totarol because the matched compound identifier rows do not contain a max-phase value.